Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

NCT01041638 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

105

Enrollment

NIH

Sponsor class

Conditions

High Risk Neuroblastoma

Interventions

BIOLOGICAL: Aldesleukin
OTHER: Diagnostic Laboratory Biomarker Analysis
BIOLOGICAL: Dinutuximab
DRUG: Isotretinoin
BIOLOGICAL: Sargramostim

Sponsor

National Cancer Institute (NCI)